Cantor Fitzgerald Comments on CRVS FY2026 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Corvus Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($0.62) per share for the year. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.13).

Several other equities analysts also recently commented on CRVS. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. Mizuho set a $11.00 target price on Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an "outperform" rating and issued a $17.00 price target (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Corvus Pharmaceuticals Trading Up 5.2%

CRVS traded up $0.21 during trading hours on Tuesday, hitting $4.25. 985,232 shares of the company's stock were exchanged, compared to its average volume of 749,605. Corvus Pharmaceuticals has a 12-month low of $1.75 and a 12-month high of $10.00. The firm has a market cap of $289.72 million, a P/E ratio of -4.57 and a beta of 0.57. The firm has a 50 day moving average of $3.48 and a 200 day moving average of $4.72.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. RTW Investments LP purchased a new position in Corvus Pharmaceuticals in the fourth quarter valued at approximately $14,335,000. Vivo Capital LLC boosted its holdings in shares of Corvus Pharmaceuticals by 49.2% in the 4th quarter. Vivo Capital LLC now owns 2,234,566 shares of the company's stock valued at $11,955,000 after buying an additional 737,298 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $8,460,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $5,350,000. Finally, Geode Capital Management LLC raised its stake in Corvus Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company's stock worth $3,034,000 after acquiring an additional 3,854 shares in the last quarter. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.